Mucosis has initiated a Phase 1 study of its SynGEM intranasal respiratory syncytial virus (RSV) vaccine, the company said. In January 2016, Mucosis announced that it had received a €3.7 million grant from the Wellcome Trust for Phase 1 and Phase 2a studies.
The Phase 1 study will be conducted at Imperial College London and will involve 48 healthy adults. The Phase 2a study is expected to begin in mid-2017 and will compare the efficacy of SynGEM to placebo in 108 adults.
According to Mucosis, the vaccine uses the company’s Mimopath technology “which uses bacterium-like particles (BLP) derived from food-grade bacteria, to deliver the antigen in a more natural conformation and boost the body’s immune response to the virus.”
Mucosis CEO Tom Johnston commented, “The start of this first-in-human study marks an important milestone in our progress towards a needle-free vaccine for prevention of RSV, a global health threat for which there is still no vaccine. We are pleased to be working with the support of the Wellcome Trust and a world-renowned university for this next step in the program, enabling us to take advantage of leading experts in the RSV field, and dedicated respiratory facilities. This second human trial of our Mimopath platform builds on the successful proof of concept trial in influenza in 2012.”
Read the Mucosis press release.
